Orforglipron vs Semaglutide

Orforglipron is an experimental oral GLP-1 drug still in development, while semaglutide is an FDA-approved injectable and oral GLP-1 treatment sold under brand names like Ozempic and Wegovy. Semaglutide is approved to treat type 2 diabetes, obesity, chronic kidney disease, and cardiovascular risk reduction, whereas Orforglipron has no approved uses yet. The main practical difference is that semaglutide is already on the market in multiple forms, while Orforglipron is still being studied.

AI summary of the sources below.